LIMITATIONS AND SUGGESTIONS
RA, T2DM
ADVERSE EVENTS
To the best of our knowledge, this study was the first to assess the effect of empagliflozin on ischemic symptoms in patients with T2DM and RA. Although we tried our best to enhance the quality of this study, several limitations exist. Our sample size was relatively small, which might affect the generalization of our findings. We followed the patients for 8 weeks, which might be relatively short for an accurate assessment of the effectiveness of our intervention or the probable occurrence of adverse events. Furthermore, we did not measure the serum level of empagliflozin in the treatment group for further assurance of proper medication consumption.